ATE531720T1 - Aza-benzofuranylverbindungen und anwendungsverfahren dafür - Google Patents
Aza-benzofuranylverbindungen und anwendungsverfahren dafürInfo
- Publication number
- ATE531720T1 ATE531720T1 AT07814272T AT07814272T ATE531720T1 AT E531720 T1 ATE531720 T1 AT E531720T1 AT 07814272 T AT07814272 T AT 07814272T AT 07814272 T AT07814272 T AT 07814272T AT E531720 T1 ATE531720 T1 AT E531720T1
- Authority
- AT
- Austria
- Prior art keywords
- aza
- methods
- benzofuranyl compounds
- benzofuranyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83916106P | 2006-08-21 | 2006-08-21 | |
| US87159106P | 2006-12-22 | 2006-12-22 | |
| US91762307P | 2007-05-11 | 2007-05-11 | |
| US94474107P | 2007-06-18 | 2007-06-18 | |
| PCT/US2007/076344 WO2008024725A1 (en) | 2006-08-21 | 2007-08-20 | Aza-benzofuranyl compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE531720T1 true ATE531720T1 (de) | 2011-11-15 |
Family
ID=38925647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07814272T ATE531720T1 (de) | 2006-08-21 | 2007-08-20 | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080085886A1 (de) |
| EP (1) | EP2069354B1 (de) |
| JP (1) | JP5448818B2 (de) |
| KR (1) | KR101428116B1 (de) |
| AR (1) | AR062468A1 (de) |
| AT (1) | ATE531720T1 (de) |
| AU (1) | AU2007286808B2 (de) |
| BR (1) | BRPI0714635A2 (de) |
| CA (1) | CA2660546A1 (de) |
| ES (1) | ES2376771T3 (de) |
| IL (1) | IL196956A (de) |
| MX (1) | MX2009001878A (de) |
| NO (1) | NO20091197L (de) |
| PE (1) | PE20080611A1 (de) |
| TW (1) | TWI411614B (de) |
| WO (1) | WO2008024725A1 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009001875A (es) * | 2006-08-21 | 2009-03-02 | Genentech Inc | Compuestos de aza-benzotiofenilo y metodos de uso de los mismos. |
| EP2227233B1 (de) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido-inhibitoren |
| EP2085390A1 (de) * | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Markierte Analoge von Halobenzamiden als multimodale Radiopharmazeutika und ihre Vorläufer |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| CA2757729A1 (en) | 2009-04-14 | 2010-10-21 | Masanori Kai | Haloalkylsulfonanilide derivative |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| MX340392B (es) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| WO2012071458A1 (en) | 2010-11-22 | 2012-05-31 | Array Biopharma Inc. | Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases |
| CA2837162C (en) | 2011-05-27 | 2019-04-02 | Bayer Intellectual Property Gmbh | Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides |
| EA026924B1 (ru) * | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| EP3563870A1 (de) | 2014-07-15 | 2019-11-06 | F. Hoffmann-La Roche AG | Verfahren zur behandlung von krebs unter verwendung von pd-1-achsen-bindenden antagonisten und mek-inhibitoren |
| EP3191126B1 (de) | 2014-09-13 | 2020-05-13 | Novartis AG | Kombinationstherapien aus alk-hemmern |
| EP3662903A3 (de) | 2014-10-03 | 2020-10-14 | Novartis AG | Kombinationstherapien |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| EP3233918A1 (de) | 2014-12-19 | 2017-10-25 | Novartis AG | Kombinationstherapien |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3316902A1 (de) | 2015-07-29 | 2018-05-09 | Novartis AG | Kombinationstherapien mit antikörpermolekülen gegen tim-3 |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| CN106883270B (zh) | 2015-11-26 | 2019-03-26 | 财团法人工业技术研究院 | 有机金属化合物、包含其的有机发光装置 |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| CN109072311A (zh) | 2016-04-15 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| ES3030506T3 (en) | 2017-05-19 | 2025-06-30 | Nflection Therapeutics Inc | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
| EP3624795B1 (de) * | 2017-05-19 | 2022-04-20 | NFlection Therapeutics, Inc. | Kondensierte heteroaromatenanilinverbindungen zur behandlung von hauterkrankungen |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| EP3752200A1 (de) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimaler resterkrankung bei krebs mit rxr-antagonisten |
| PE20211916A1 (es) | 2018-05-24 | 2021-09-28 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| CA3120337A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| JP7546297B2 (ja) | 2018-11-20 | 2024-09-06 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのチエニル－アニリン化合物 |
| MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113747944A (zh) | 2019-04-19 | 2021-12-03 | 詹森生物科技公司 | 用抗psma/cd3抗体治疗前列腺癌的方法 |
| TW202135859A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 組合療法 |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP2024504758A (ja) | 2021-01-28 | 2024-02-01 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｓｍａ結合タンパク質及びその使用 |
| KR20230170644A (ko) | 2021-02-02 | 2023-12-19 | 르 라보레또레 쎄르비에르 | 선택적 bcl-xl protac 화합물 및 사용 방법 |
| EP4308935A1 (de) | 2021-03-18 | 2024-01-24 | Novartis AG | Biomarker für krebs und verfahren zur verwendung davon |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| US20250339547A1 (en) | 2022-05-20 | 2025-11-06 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| EP4676540A1 (de) | 2023-03-10 | 2026-01-14 | Novartis AG | Panras-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon |
| TW202540185A (zh) | 2023-11-22 | 2025-10-16 | 法商施維雅藥廠 | 抗cd74抗體藥物結合物及其使用方法 |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
| WO2026019990A1 (en) | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
| CN119285968B (zh) * | 2024-09-19 | 2025-06-20 | 黑龙江大学 | 一种光致变色稀土聚合物及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328920A (en) * | 1991-04-17 | 1994-07-12 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted (pyridinylamino)-indoles |
| US5214204A (en) * | 1991-07-19 | 1993-05-25 | Abbott Laboratories | Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity |
| DE69216509T2 (de) * | 1991-08-12 | 1997-05-28 | Takeda Chemical Industries Ltd | Kondensierte Pyrimidinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel |
| CA2083891A1 (en) * | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
| JPH05345780A (ja) * | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
| US5852046A (en) * | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| US5350748A (en) * | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
| DE4425609A1 (de) * | 1994-07-20 | 1996-01-25 | Bayer Ag | Benzofuranyl- und Benzothienyloxazolidinone |
| FR2777886B1 (fr) * | 1998-04-27 | 2002-05-31 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6410562B1 (en) * | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| HRP20010524A2 (en) * | 1999-01-13 | 2002-08-31 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| FR2799756B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2416685C (en) * | 2000-07-19 | 2008-10-07 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| DE10110750A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6653346B1 (en) * | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| DE60330227D1 (de) * | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| RU2300528C2 (ru) * | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек |
| US20040009976A1 (en) * | 2002-04-30 | 2004-01-15 | Kumiko Takeuchi | Hypoglycemic imidazoline compounds |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| JP2005104838A (ja) * | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| DE10351436A1 (de) * | 2003-11-04 | 2005-06-09 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| WO2005061476A2 (en) * | 2003-12-22 | 2005-07-07 | Basilea Pharmaceutica Ag | Aroylfuranes and aroylthiophenes |
| MX2007012448A (es) * | 2005-04-06 | 2007-10-19 | Astrazeneca Ab | Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak. |
| AU2006284751A1 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| MX2009001875A (es) * | 2006-08-21 | 2009-03-02 | Genentech Inc | Compuestos de aza-benzotiofenilo y metodos de uso de los mismos. |
| MX2009003102A (es) * | 2006-09-21 | 2009-04-01 | Wyeth Corp | INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA. |
-
2007
- 2007-08-20 EP EP07814272A patent/EP2069354B1/de active Active
- 2007-08-20 WO PCT/US2007/076344 patent/WO2008024725A1/en not_active Ceased
- 2007-08-20 CA CA002660546A patent/CA2660546A1/en not_active Abandoned
- 2007-08-20 JP JP2009525720A patent/JP5448818B2/ja not_active Expired - Fee Related
- 2007-08-20 KR KR1020097005786A patent/KR101428116B1/ko not_active Expired - Fee Related
- 2007-08-20 MX MX2009001878A patent/MX2009001878A/es active IP Right Grant
- 2007-08-20 AT AT07814272T patent/ATE531720T1/de active
- 2007-08-20 BR BRPI0714635-3A patent/BRPI0714635A2/pt not_active IP Right Cessation
- 2007-08-20 ES ES07814272T patent/ES2376771T3/es active Active
- 2007-08-20 AU AU2007286808A patent/AU2007286808B2/en not_active Ceased
- 2007-08-20 US US11/894,506 patent/US20080085886A1/en not_active Abandoned
- 2007-08-21 AR ARP070103712A patent/AR062468A1/es unknown
- 2007-08-21 PE PE2007001135A patent/PE20080611A1/es not_active Application Discontinuation
- 2007-08-21 TW TW096130982A patent/TWI411614B/zh not_active IP Right Cessation
-
2009
- 2009-02-09 IL IL196956A patent/IL196956A/en not_active IP Right Cessation
- 2009-03-20 NO NO20091197A patent/NO20091197L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL196956A0 (en) | 2009-11-18 |
| CA2660546A1 (en) | 2008-02-28 |
| KR20090042332A (ko) | 2009-04-29 |
| AR062468A1 (es) | 2008-11-12 |
| NO20091197L (no) | 2009-05-20 |
| TWI411614B (zh) | 2013-10-11 |
| MX2009001878A (es) | 2009-03-03 |
| ES2376771T3 (es) | 2012-03-16 |
| JP5448818B2 (ja) | 2014-03-19 |
| PE20080611A1 (es) | 2008-07-21 |
| AU2007286808B2 (en) | 2012-12-06 |
| WO2008024725A1 (en) | 2008-02-28 |
| BRPI0714635A2 (pt) | 2013-06-18 |
| EP2069354B1 (de) | 2011-11-02 |
| US20080085886A1 (en) | 2008-04-10 |
| EP2069354A1 (de) | 2009-06-17 |
| IL196956A (en) | 2014-04-30 |
| KR101428116B1 (ko) | 2014-08-07 |
| JP2010501585A (ja) | 2010-01-21 |
| TW200817415A (en) | 2008-04-16 |
| AU2007286808A1 (en) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE531720T1 (de) | Aza-benzofuranylverbindungen und anwendungsverfahren dafür | |
| EP2094085A4 (de) | Anti-cholesterin-verbindungen und anwendungsverfahren dafür | |
| CY2019010I2 (el) | Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης | |
| HUS2100009I1 (hu) | Halauxifen-metil és piroxszulam kombinációja | |
| ATE511509T1 (de) | Azaindolylverbindungen und anwendungsverfahren | |
| CY2020021I1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
| EP2079544A4 (de) | Arsenabsorbierende zusammensetzung und verwendungsverfahren | |
| IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
| PL2152256T3 (pl) | Związki aktywujące telomerazę i sposoby ich zastosowania | |
| IL198397A0 (en) | Anilinopiperazine derivatives and methods of use thereof | |
| DE602007010272D1 (de) | Parkhilfevorrichtung und parkhilfeverfahren | |
| CR10815A (es) | Nuevos derivados de isoquinolina e isoquinolinona sustituidos | |
| EP2122054A4 (de) | Vliestafel und konstruktionsverfahren dafür | |
| DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
| ATE526567T1 (de) | Zusammensteller und zusammenstellungsverfahren | |
| EP1845849A4 (de) | Exoskelett für die beine | |
| IL194028A0 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| BRPI0909954A2 (pt) | "diazacarbazóis e métodos de uso" | |
| EP2066174A4 (de) | Zusammensetzungen mit alpha-1-antitrypsin und verwendungsverfahren dafür | |
| HRP20141261T1 (xx) | Spojevi tioninija i njihove uporabe | |
| DK2069467T3 (da) | Adskillende sammensætninger og fremgangsmåder til anvendelse | |
| IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
| ZA201000183B (en) | Quinazolinone compounds and methods of use thereof | |
| EP2139325A4 (de) | Anti-angiogenese-mittel und anwendungsverfahren dafür | |
| FI20065757L (fi) | Beta-laktamaasin käyttö |